Misplaced Pages

Allisartan isoproxil: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactivelyContent deleted Content addedVisualWikitext
Revision as of 22:38, 3 January 2025 editInnerstream (talk | contribs)Autopatrolled, Extended confirmed users4,071 edits new pageTag: nowiki added  Latest revision as of 21:49, 7 January 2025 edit undoGraeme Bartlett (talk | contribs)Administrators249,755 edits chemspider 
(5 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{cs1 config|name-list-style=vanc|display-authors=6}}
{{Infobox drug {{Infobox drug
| drug_name = | drug_name =
Line 51: Line 52:
| PubChem = 24748496 | PubChem = 24748496
| UNII = DI4662MK4N | UNII = DI4662MK4N
| ChemSpiderID = 57583156
| DrugBank = DB18880 | DrugBank = DB18880
<!-- Chemical and physical data --> <!-- Chemical and physical data -->
Line 60: Line 62:
}} }}


'''Allisartan isoproxil''' is an ] pharmaceutical drug.<ref>{{cite journal | pmid = 30896643 }}</ref><ref>{{cite journal | pmid = 38903964 }}</ref><ref>{{cite journal | pmid = 37343187 }}</ref> It belongs to the ] class of drugs. It is an ]ified ],<ref>{{cite journal | pmc = 11187348 }}</ref> and its metabolism results in the formation of a single metabolite, losartan carboxylic acid (EXP3174), an oxidized form of ]. '''Allisartan isoproxil''' is an ] pharmaceutical drug.<ref>{{cite journal | vauthors = Zhang JQ, Yang GH, Zhou X, Liu JX, Shi R, Dong Y, Chen SB, Li YM | title = Effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension | journal = Medicine | volume = 98 | issue = 12 | pages = e14907 | date = March 2019 | pmid = 30896643 | pmc = 6708765 | doi = 10.1097/MD.0000000000014907 }}</ref><ref name=Zhao>{{cite journal | vauthors = Zhao F, Liu Y, Chen L | title = Efficacy and safety evaluation of Allisartan Isoproxil in patients with hypertension: a meta-analysis | journal = Frontiers in Cardiovascular Medicine | volume = 11 | pages = 1355014 | date = 2024 | pmid = 38903964 | pmc = 11187348 | doi = 10.3389/fcvm.2024.1355014 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Wang H, Xi Y, Chen Y, Wang L, Yang F, Lu X, Sun N | title = Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension | journal = American Journal of Hypertension | volume = 36 | issue = 10 | pages = 561–567 | date = September 2023 | pmid = 37343187 | doi = 10.1093/ajh/hpad055 }}</ref> It belongs to the ] class of drugs. It is an ]ified ],<ref name=Zhao/> and its metabolism results in the formation of a single metabolite, losartan carboxylic acid (EXP3174), an oxidized form of ].


:]{{clear-left}} :]{{clear-left}}


In China, allisartan isoproxil was approved by the Chinese Food and Drug Administration for the treatment of ] in 2012, and introduced to the market in 2013.<ref>{{cite journal | doi = 10.1038/s41401-021-00684-7 }}</ref> In China, allisartan isoproxil was approved by the Chinese Food and Drug Administration for the treatment of ] in 2012, and introduced to the market in 2013.<ref>{{cite journal | vauthors = Ling QS, Zhang SL, Tian JS, Cheng MH, Liu AJ, Fu FH, Liu JG, Miao CY | title = Allisartan isoproxil reduces mortality of stroke-prone rats and protects against cerebrovascular, cardiac, and aortic damage | journal = Acta Pharmacologica Sinica | volume = 42 | issue = 6 | pages = 871–884 | date = June 2021 | pmid = 34002042 | pmc = 8149727 | doi = 10.1038/s41401-021-00684-7 }}</ref>


==References== == References ==
{{reflist}} {{reflist}}


] ]
] ]
⚫ ]
] ]
] ]
] ]
]
]
]
] ]
⚫ ]

Latest revision as of 21:49, 7 January 2025

Pharmaceutical compound
Allisartan isoproxil
Identifiers
IUPAC name
  • Propan-2-yloxycarbonyloxymethyl 2-butyl-5-chloro-3-phenyl]methyl]imidazole-4-carboxylate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
Chemical and physical data
FormulaC27H29ClN6O5
Molar mass553.02 g·mol
3D model (JSmol)
SMILES
  • CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCOC(=O)OC(C)C)Cl
InChI
  • InChI=1S/C27H29ClN6O5/c1-4-5-10-22-29-24(28)23(26(35)37-16-38-27(36)39-17(2)3)34(22)15-18-11-13-19(14-12-18)20-8-6-7-9-21(20)25-30-32-33-31-25/h6-9,11-14,17H,4-5,10,15-16H2,1-3H3,(H,30,31,32,33)
  • Key:XMHJQQAKXRUCHI-UHFFFAOYSA-N

Allisartan isoproxil is an antihypertensive pharmaceutical drug. It belongs to the angiotensin II receptor blocker class of drugs. It is an esterified prodrug, and its metabolism results in the formation of a single metabolite, losartan carboxylic acid (EXP3174), an oxidized form of losartan.

Chemical structure of losartan carboxylic acid

In China, allisartan isoproxil was approved by the Chinese Food and Drug Administration for the treatment of hypertension in 2012, and introduced to the market in 2013.

References

  1. Zhang JQ, Yang GH, Zhou X, Liu JX, Shi R, Dong Y, et al. (March 2019). "Effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension". Medicine. 98 (12): e14907. doi:10.1097/MD.0000000000014907. PMC 6708765. PMID 30896643.
  2. ^ Zhao F, Liu Y, Chen L (2024). "Efficacy and safety evaluation of Allisartan Isoproxil in patients with hypertension: a meta-analysis". Frontiers in Cardiovascular Medicine. 11: 1355014. doi:10.3389/fcvm.2024.1355014. PMC 11187348. PMID 38903964.
  3. Wang H, Xi Y, Chen Y, Wang L, Yang F, Lu X, et al. (September 2023). "Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension". American Journal of Hypertension. 36 (10): 561–567. doi:10.1093/ajh/hpad055. PMID 37343187.
  4. Ling QS, Zhang SL, Tian JS, Cheng MH, Liu AJ, Fu FH, et al. (June 2021). "Allisartan isoproxil reduces mortality of stroke-prone rats and protects against cerebrovascular, cardiac, and aortic damage". Acta Pharmacologica Sinica. 42 (6): 871–884. doi:10.1038/s41401-021-00684-7. PMC 8149727. PMID 34002042.
Categories: